| Description |
Recombinant Biotinylated Human HLA-A*02:01&B2M&KRAS G12V (KLVVVGAVGV) Monomer Protein is expressed from E.coli with His tag and Avi tag at the C-terminus.It contains Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and KLVVVGAVGV peptide. |
| Purity |
> 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
| Accession |
A0A140T913(HLA-A*02:01)&P61769(B2M)&KLVVVGAVGV |
| Target Symbol |
HLA-A*02:01&B2M&KRAS G12V (KLVVVGAVGV) Monomer |
| Species |
Human |
| Expression System |
E. coli |
| Tag |
C-His-Avi |
| Expression Range |
Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and KLVVVGAVGV peptide |
| Mol. Weight |
The protein has a predicted MW of 35.6 kDa (HLA-A*02:01) and 11.9 kDa (B2M) same as Tris-Bis PAGE result. |
| Form |
Liquid |
| Formulation |
Supplied as 0.22 um filtered solution in PBS (pH 7.4). |
| Endotoxin |
Less than 1EU per ug by the LAL method. |
| Storage |
Valid for 12 months from date of receipt when stored at -80°C.； Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles. |
| Shipping |
Shipped with dry ice. |
| Gene Background |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. |
